Comparative Efficacy and Safety of Oral Tofacitinib Plus PUVASOL Versus Oral Betamethasone Plus PUVASOL in Adults with Vitiligo: A Randomized Controlled Trial
International Journal of Current Pharmaceutical Review and Research · 30.04.2026 · 18 (04)
DOI: 10.25258/ijcpr.18.4.263 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.04.2026. Verfasst von Supriya Behera und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Rapidly progressive vitiligo often requires systemic therapy to arrest activity and induce repigmentation. Oral corticosteroid mini-pulse regimens are widely used, whereas oral Janus kinase inhibition is an emerging targeted strategy. Comparative data between these approaches in combination with psoralensunlight therapy remain limited.
Aim
To compare the efficacy and safety of oral tofacitinib plus PUVASOL versus oral betamethasone plus PUVASOL in adults with vitiligo.
Methods
This randomized controlled trial was conducted in the Department of Dermatology, SCB Medical College and Hospital, between August 2022 and December 2023. Forty patients were enrolled and 36 completed follow-ups. Participants were randomized 1:1 to oral tofacitinib 5 mg twice daily plus oral PUVASOL or oral betamethasone pulse therapy plus oral PUVASOL for 24 weeks. VASI was recorded at baseline, week 12, and week 24. Efficacy analyses included within-group and between-group comparisons, responder analysis, and repeated-measures mixed-effects modeling. Adverse events were recorded in both groups.
Results
Eighteen patients were analyzed in each arm. Both groups showed significant within-group VASI reduction at week 12 and week 24 (all P < 0.001). Mean absolute VASI reduction at week 24 was 3.12 ± 2.62 with betamethasone and 3.64 ± 2.70 with tofacitinib (P = 0.535). Mean percentage VASI reduction at week 24 was 30.63 ± 14.23% and 27.49 ± 9.37%, respectively (P = 0.566). Betamethasone showed greater early percentage reduction at week 12 (P = 0.045), but this was not sustained. Mixed-effects analysis confirmed a significant time effect (P < 0.001) without a significant group × time interaction (P = 0.716). Adverse events were mild in both groups.
Conclusion
Both oral betamethasone plus PUVASOL and oral tofacitinib plus PUVASOL significantly improved vitiligo severity over 24 weeks. In this study, tofacitinib did not show superiority over betamethasone for short-term VASI improvement, although both regimens were well tolerated and clinically active.
Zitieren
APA
Behera, S., Parida, D., & Mohanty, P. (2026). Comparative Efficacy and Safety of Oral Tofacitinib Plus PUVASOL Versus Oral Betamethasone Plus PUVASOL in Adults with Vitiligo: A Randomized Controlled Trial. International Journal of Current Pharmaceutical Review and Research, 18(04). https://doi.org/10.25258/ijcpr.18.4.263
Vancouver
Behera S, Parida D, Mohanty P. Comparative Efficacy and Safety of Oral Tofacitinib Plus PUVASOL Versus Oral Betamethasone Plus PUVASOL in Adults with Vitiligo: A Randomized Controlled Trial. International Journal of Current Pharmaceutical Review and Research. 2026;18(04). doi:10.25258/ijcpr.18.4.263
BibTeX
@article{Behera2026,
author = {Behera, Supriya and Parida, Debasisha and Mohanty, Prasenjeet},
title = {Comparative Efficacy and Safety of Oral Tofacitinib Plus PUVASOL Versus Oral Betamethasone Plus PUVASOL in Adults with Vitiligo: A Randomized Controlled Trial},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {04},
doi = {10.25258/ijcpr.18.4.263}
}
EUVIMED